COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Long-term Peg Intron vs. Colchicine in Non-responders. (COPILOT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00179413
Recruitment Status : Completed
First Posted : September 16, 2005
Results First Posted : July 11, 2017
Last Update Posted : July 11, 2017
Information provided by (Responsible Party):
Nezam H. Afdhal, Beth Israel Deaconess Medical Center

Brief Summary:
In this study Peg-Intron will be tested to see if it will give better results than Colchicine. At this time, there is currently no recommended maintenance treatment for patients who have failed to respond to Interferon/Rebetron/Peg Intron and have advanced fibrosis. The purpose of this study is to compare two treatments to slow down the progression of liver disease and to prevent liver failure and liver cancer. The treatment will not cure Hepatitis C, but is being evaluated to see if it can slow down disease progression.

Condition or disease Intervention/treatment Phase
Hepatitis C Virus Advanced Fibrosis Cirrhosis Drug: PEG -Intron Drug: Colchicine Phase 4

Detailed Description:

We are proposing a randomized trial of Peg-Intron 0.5mcg per kg weekly versus colchicine 0.6mg bid in prior non-responders to Interferon, Rebetron, PegIntron, or PegIntron & Ribavirin or any third agent such as Pegasys, CellCept, Amantadine with advanced fibrosis/cirrhosis. The specific aims of this proposal are to evaluate the role of long term Peg-Intron therapy on the natural history of patients with advanced chronic HCV infection with a primary focus on prevention of hepatic decompensation, progression of fibrosis and hepatoma development.

The study design will focus on 3 monthly clinical evaluation for decompensation of liver function, rigorous clinical screening for development of hepatocellular cancer and liver biopsies for determination of progression of liver fibrosis every second year.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 549 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial
Actual Study Start Date : January 15, 2000
Actual Primary Completion Date : December 31, 2009
Actual Study Completion Date : March 3, 2010

Arm Intervention/treatment
Active Comparator: PEG-Intron
PEG-Intron 0.5mcg/kg once a week SC
Drug: PEG -Intron
Other Name: PEG interferon Alfa-2b 0.5mcg/kg weekly

Active Comparator: Colchicine
0.6mg twice a day
Drug: Colchicine
0.6mg twice a day

Primary Outcome Measures :
  1. Determination of the Effect of PEG-Intron 0.5mg Per kg Weekly sc Versus Colchicine 0.6mg Bid Daily on: [ Time Frame: 4 years ]
    number of patients with a liver related outcomes including: mortality, liver transplant, variceal or portal hypertensive bleeding,Development of jaundice, ascites or encephalopathy with an increase in CPT of > 2 points and development of hepatoma

Secondary Outcome Measures :
  1. Evaluation of Safety and Tolerability of Long Term Maintenance PEG-Intron in Patients With Cirrhosis [ Time Frame: 4 years ]
    Defined as the number of patients who discontinued therapy due to an adverse event side

  2. Development of Portal Hypertension [ Time Frame: 4 years ]
    Number of patients who develop endoscopic evidence of varices over 4 year period

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • *Adult male or female, age 18 to 75 years

    • HCV RNA positive by PCR
    • Previous treatment with at least three months of interferon or interferon / Ribavirin. Patients should have had no interferon for at least 2 months prior to enrollment.

      1. Non-responders are identified by failure to clear virus by PCR after a minimum 3-month course of treatment and who have been off treatment for at least 2 months with a positive PCR for HCV prior to entry into the current study, 2) Partial responders have a reduction of 1 long in HCV RNA, but the virus is still detectable, 3) Breakthrough patients have been negative on treatment, but virus appeared while still on treatment, 4) Relapsers are defined as negative PCR at some point during treatment, but virus reoccurred or was detectable by HCV PCR when treatment stopped.

Patients should have had a liver biopsy showing at least Stage 3 disease prior to being considered for this study. A baseline liver biopsy is necessary for inclusion in the study. Baseline liver biopsies can be performed within six months of entering the study.

In patients with cirrhosis and endoscopic evidence of portal hypertension, a biopsy within the last 2 years is acceptable as the baseline biopsy. For patients with established cirrhosis on liver biopsy and no portal hypertension, a biopsy within 12 months can be used as the baseline biopsy if it is available for evaluation by the Pathology core. All these patients will still require liver biopsy at 2 years and 4 years. The decision to biopsy at 2 and 4 years is also a clinical decision and in the presence of clinical progression or coagulopathy, or where there may be a risk from liver biopsy, the Investigator should call the PI, Dr. Afdhal for a waiver of biopsy. Patients with Ishak Stage 3 and 4 require a biopsy within 6 months of randomization.

  • Hemoglobin >= 11 g/dl in males and 10 g/dl in females
  • Neutrophil count > 1,500/mm3
  • Platelets > 50, 000/mm3

Platelet count: For standard dose of PEG-Intron 0.5mcg/kg platelet count must be greater than 70,000. Patients with platelet count 50 - 70,000 can start at 0.25mcg/kg for weeks 0 - 4. If platelets fall to less than 30,000, stop treatment. If platelets remain > 50,000 at week 4, PEG-Intron can be increased to 0.5mcg/kg. Patients randomized to Colchicine with platelets 50,000 - 70,000 can be started at standard dose 0.6mg bid po with standard dose reduction.

  • Prothrombin time <= 3secs prolonged compared to control or an equivalent INR < 1.5
  • Total bilirubin < 3gm/dL
  • Fasting blood sugar <= 115 mg/dl or within 20% of the upper limit of normal for non-diabetic patients
  • Albumin (> 2.8mg/dl)
  • Serum creatinine < 1.4 mg/dL
  • TSH within the normal range (Patients with thyroid disease who are well controlled are eligible if the remainder of the inclusion/exclusion criteria are met)
  • HIV negative.

    • HBsAg negative
    • Childs Pugh score of less than or equal to 7
    • Serum positive for anti-hepatitis C antibodies or HCV RNA.
    • Alpha-fetoprotein < 100ng/ml with ultrasound negative for focal mass or HCC. For any patient with an Alpha-fetoprotein >100 ng/ml either a triple phase contrast CT scan or MRI with gadolinium must show no focal mass or evidence of HCC
    • Ultrasound with no evidence of focal mass suggestive of hepatoma (within 6 months of informed consent).
    • Documentation that sexually active female patients of childbearing potential are practicing adequate contraception during the treatment period. A urine pregnancy test obtained at entry prior to the initiation of treatment must be negative. Female patients must not be breast-feeding. Documentation that sexually active male patients are practicing acceptable methods of contraception during the treatment period.
    • Written informed consent specific for this protocol has been obtained prior to entry.

Exclusion Criteria:

  • Any cause of liver disease based on patient history and biopsy (where applicable) other than chronic hepatitis C including but not limited to:

    • Co-infection with hepatitis B or HIV
    • Hemochromatosis (confirmed by genetic testing)
    • Alpha-1 antitrypsin deficiency
    • Wilson's disease
    • Renal or liver transplant patients
    • Autoimmune hepatitis
    • Alcoholic liver disease
    • Obesity induced liver disease
    • Drug related liver disease

In addition:

  • Evidence of decompensated liver disease such as a history or presence of ascites, and spontaneous encephalopathy. Patients with past bleeding esophageal varices that have not bled for more than 1 year can be included.
  • Hypersensitivity to alpha interferon
  • Drug related liver disease
  • Hemoglobinopathies (e.g. Thalassaemia, sickle cell disease).
  • Patients with clinically significant retinal abnormalities.
  • Substance abuse, such as alcohol (·> 80 gm/day), I.V. drugs and inhaled drugs. If the patient has a history of substance abuse, to be considered for inclusion into the protocol, the patient must have abstained from using the abused substance for at least 6 months. Patients on methadone will be allowed in the study with no restrictions as is now standard of care in HCV therapy.
  • Patients with a history of organ transplantation will be excluded.

Preexisting psychiatric conditions, especially depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt are excluded. Patients with a history of mild depression may enter the protocol if they meet the following eligibility criterion and are monitored more intensively.

Mild depression: to include either situational depression of a limited period or depressive symptoms, which do not significantly interfere with the patient's work or daily functions.

Any patient with an active manic element to his/her previous symptom complex will be excluded.

Any known pre-existing medical condition that could interfere with the patient's participation in and completion of the study such as:

  • Pre-existing psychiatric condition, especially severe depression, or a history of severe psychiatric disorder
  • CNS trauma or seizure disorder requiring therapy
  • Significant cardiac dysfunction in the previous 6 months e.g. angina, CCF, hypertension or arrhythmia Patients on treatment are eligible as long as they have been symptom free for the previous 6 months.
  • Poorly controlled diabetes mellitus
  • Chronic pulmonary disease (e.g. COAD)
  • Immunologically mediated diseases (e.g. inflammatory bowel disease, SLE, ITP, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis, severe psoriasis)
  • Clinical gout
  • Patients with clinically significant retinal abnormalities
  • Patients with organ transplants

Any other condition, which in the view of the investigator, would make the patient unsuitable for enrolment, or could interfere with the patient participating in and completing the protocol are included as well.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00179413

Show Show 49 study locations
Sponsors and Collaborators
Beth Israel Deaconess Medical Center
Layout table for investigator information
Principal Investigator: Nezam H Afdhal, MD Beth Israel Deaconess Medical Center

Layout table for additonal information
Responsible Party: Nezam H. Afdhal, Professor of Medicine, Part-time, Beth Israel Deaconess Medical Center Identifier: NCT00179413    
Other Study ID Numbers: 2001P000002
First Posted: September 16, 2005    Key Record Dates
Results First Posted: July 11, 2017
Last Update Posted: July 11, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Nezam H. Afdhal, Beth Israel Deaconess Medical Center:
hepatitis C
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Liver Cirrhosis
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Pathologic Processes
Flaviviridae Infections
Interferon alpha-2
Peginterferon alfa-2b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Gout Suppressants
Antirheumatic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action